The ASEA lawsuit history is shorter than the company’s marketing controversy might suggest. ASEA LLC, the Utah direct-selling company behind a “redox signaling” supplement, has been directly involved in two known legal or regulatory matters: a 2017 trademark infringement suit it filed in federal court in Utah, and a 2023 ruling against it by the UK’s Advertising Standards Authority over health claims. A separate 2022 federal lawsuit in Florida did not name ASEA but discussed the origin and finances of its flagship product. No public record shows FDA or FTC enforcement action against the company as of early 2026.
The 2023 UK Advertising Standards Authority Ruling
The most significant regulatory action against ASEA to date came on May 24, 2023, when the UK’s Advertising Standards Authority upheld a complaint against ASEA LLC over marketing for the ASEA REDOX Cell Signalling Supplement. The ASA found the advertisement breached the CAP Code on three grounds.1Advertising Standards Authority. ASEA LLC Ruling A22-1177357
First, the ad made specific health claims — including that the product “Improves Immune system function,” “Increases VO2 Max,” and “Increases burn of fat fuels by up to 33%” — that were not authorized on Great Britain’s nutrition and health claims register. Second, it made general health claims such as “Improves cardiovascular health” without pairing them with an authorized specific health claim, as UK rules require. Third, the ad implied the product could treat or prevent disease, pointing to claims that it could “Regulate Inflammatory response” and achieved a “100% kill in under 30 seconds for all tested bacteria and viruses.”1Advertising Standards Authority. ASEA LLC Ruling A22-1177357
The ASA ordered that the advertisement must not appear again in that form and barred ASEA from making unauthorized health claims or claims that the product could treat, prevent, or cure human disease. ASEA told the ASA that the advertisement had been produced by an independent distributor and was not approved for use in the UK, and said it would take steps to prevent its reuse. The response reflects a recurring issue for the company: a decentralized network of independent associates sells and promotes the product, and some of those associates make claims the company does not stand behind.
The 2017 Trademark Case: ASEA LLC v. Pack
In February 2017, ASEA LLC filed a trademark infringement suit against James G. Pack in the U.S. District Court for the District of Utah. The case, 2:17-cv-00079, was assigned to Judge Bruce S. Jenkins. ASEA, represented by Kirton McConkie, sought preliminary injunctive relief over what it alleged was unauthorized use of its trademarks.2PACER Monitor. ASEA LLC v. Pack
The litigation ended quickly. On May 19, 2017, the court granted a stipulated motion to dismiss with prejudice, meaning the parties reached an agreement and ASEA could not refile the same claims. The terms are not public.
Avini Health v. Biogenus: Related, But Not Against ASEA
A 2022 federal lawsuit in the Southern District of Florida, Avini Health Corporation v. Biogenus LLC (0:22-cv-61992), did not name ASEA as a party but is often read alongside the company’s legal profile because of what it said about ASEA’s product. Avini sued Biogenus and its principal, Gary Samuelson, over a breached supply agreement for nano-silver and redox products. Samuelson had represented himself to Avini as “instrumental in the development” of ASEA’s REDOX product and “the key person” behind its formulation.3GovInfo. Avini Health Corporation v. Biogenus LLC
The complaint estimated that ASEA’s redox product generates roughly $180 million in annual sales and $60 million in annual profit. Avini alleged that Samuelson developed an improved version of the redox product and, rather than offering it under a right-of-first-refusal clause, sold it directly to Avini’s distributors at $25 per bottle while telling Avini the product was not yet ready.4Justia. Avini Health Corporation v. Biogenus LLC
Biogenus did not respond, and the court entered a default judgment awarding Avini $210,000 in compensatory damages — $205,000 for delivery of defective nano-silver products and $5,000 for the right-of-first-refusal breach — along with $42,355 in attorneys’ fees and $1,985.75 in costs. The court denied Avini’s request for a permanent injunction and specific performance, reasoning that the redox product was not sufficiently “unique” given alternatives on the market, including ASEA’s.3GovInfo. Avini Health Corporation v. Biogenus LLC The underlying agreement between Avini and Biogenus expired on March 1, 2024.
U.S. Regulators and the BBB Record
No public record indicates that the U.S. Food and Drug Administration or the Federal Trade Commission has taken formal enforcement action against ASEA LLC as of early 2026. The UK’s ASA ruling remains the most significant regulatory action against the company.
ASEA LLC holds an A+ rating from the Better Business Bureau and has been BBB-accredited since June 2015. A BBB rating reflects responsiveness to the BBB’s process, not an endorsement of the product. Reviewers have cited a lack of scientific validation for product claims and difficulty verifying anecdotal testimonies. One reviewer reported spending more than $200 per month for six months on the product and business opportunity without positive results.5Better Business Bureau. ASEA LLC BBB Business Profile
Why the Claims Keep Drawing Scrutiny
The regulatory and consumer complaints track a scientific record that gives ASEA’s marketing little support. Dr. Joe Schwarcz of McGill University’s Office for Science and Society reviewed the product and concluded its ingredients amount to “distilled water and salt.” He called the term “Redox Signaling supplement” “meaningless double talk” and said the promotional materials he reviewed contained no scientific data, only testimonials he attributed to a placebo effect.6McGill University Office for Science and Society. Can ASEA Improve Health as Advertised
A double-blind, placebo-controlled trial by Utah State University researchers, published in the Journal of Exercise Physiology in 2019, had 11 young adults consume ASEA daily for two weeks and found no statistically significant improvement in VO2 max, time to exhaustion, ventilatory threshold, or maximal heart rate compared with placebo. The authors wrote that “contrary to the manufacturer’s claims, ASEA did not improve the aerobic performance of young, fit adults.”7Utah State University Digital Commons. ASEA and Aerobic Performance Study They also noted that despite the product’s years on the market, there had been virtually no independent peer-reviewed research on its efficacy before their study. That gap between marketing and evidence is the thread connecting the UK ruling, the BBB complaints, and the public criticism from independent scientists.